Midline-1 inhibited high glucose-induced epithelial-mesenchymal transition, fibrosis and inflammation through WNT/β-catenin signaling in benign prostatic hyperplasia
In general, our novel data demonstrate targeting MID1 might be a promising area of medical treatment for patients with both BPH and diabetes.
Authors
- Jiang Liu (ORCID: https://orcid.org/0000-0002-4409-1157)
- Yongying Zhou (ORCID: https://orcid.org/0000-0002-4378-8163)
- Daoquan Liu (ORCID: https://orcid.org/0000-0002-2628-0229)
- Ping Chen (ORCID: https://orcid.org/0000-0003-0427-2428)
- Michael E. DiSanto (ORCID: https://orcid.org/0000-0003-4754-7794)
- Hongjun Li (ORCID: https://orcid.org/0000-0002-1765-8445)
- Xinhua Zhang (ORCID: https://orcid.org/0000-0003-0267-428X)
- Hao Zhang
- Zhen Wang
- Yan Li (ORCID: https://orcid.org/0000-0003-4936-8917)
- Xun Fu (ORCID: https://orcid.org/0009-0002-8121-1055)
- Shangjing Yang
Institutions
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Peking Union Medical College Hospital (CN)
- Wuhan University (CN)
- Cooper Medical School of Rowan University (US)
- Zhongnan Hospital of Wuhan University (CN)
Publication Details
- Journal
- Frontiers in Endocrinology
- Published
- 2025-03-26
- DOI
- https://doi.org/10.3389/fendo.2025.1543295
- Citations
- 1
- Primary Topic
- Urinary Bladder and Prostate Research
- Type
- article
- Field-Weighted Citation Impact
- 1.84
Funders
- National Natural Science Foundation of China